Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$11.37 -0.5%	$8.70	$5.29 ▼ $11.80	$1.50B	1.23	2.62 million shs	2.50 million shs
AXSM Axsome Therapeutics	$104.80 +0.5%	$105.86	$75.56 ▼ $139.13	$5.23B	0.51	653,203 shs	311,364 shs
NUVL Nuvalent	$74.11 +2.7%	$78.99	$55.53 ▼ $113.51	$5.32B	1.3	521,588 shs	891,894 shs
RYTM Rhythm Pharmaceuticals	$91.98 -0.5%	$75.37	$43.57 ▼ $94.80	$6.11B	2.38	609,756 shs	819,638 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	+8.39%	+29.20%	+40.02%	+110.56%
AXSM Axsome Therapeutics	0.00%	+1.73%	-3.84%	-4.87%	+26.13%
NUVL Nuvalent	0.00%	-4.69%	-8.43%	+0.65%	+5.89%
RYTM Rhythm Pharmaceuticals	0.00%	+4.17%	+6.09%	+55.98%	+103.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.3357 of 5 stars	1.5	1.0	0.0	3.4	2.5	3.1
AXSM Axsome Therapeutics	4.8055 of 5 stars	4.5	3.0	4.5	2.5	4.2	0.6
NUVL Nuvalent	3.1285 of 5 stars	4.5	1.0	0.0	2.5	3.3	0.0
RYTM Rhythm Pharmaceuticals	3.9996 of 5 stars	3.5	2.0	4.3	3.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	5.54% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	69.85% Upside
NUVL Nuvalent	3.09	Buy	$119.60	61.38% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$101.57	10.43% Upside

Current Analyst Ratings Breakdown

Latest AUPH, RYTM, NUVL, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $100.00
8/6/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$119.00 ➝ $120.00
8/6/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$130.00 ➝ $135.00
8/5/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $109.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/21/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	6.37	$0.31 per share	36.87	$2.68 per share	4.24
AXSM Axsome Therapeutics	$385.69M	13.56	N/A	N/A	$1.18 per share	88.81
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
RYTM Rhythm Pharmaceuticals	$130.13M	46.95	N/A	N/A	$0.35 per share	262.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	26.44	20.30	N/A	23.31%	20.06%	13.81%	N/A
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	37.16	N/A	-49.88%	-283.22%	-33.06%	N/A
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-32.58%	-30.14%	8/14/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$3.01	N/A	N/A	N/A	-117.13%	-1,831.43%	-48.33%	N/A

Latest AUPH, RYTM, NUVL, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.66	-$0.75	-$0.09	-$0.75	$43.72 million	$48.50 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
AXSM Axsome Therapeutics	1.66	1.57	1.96
NUVL Nuvalent	N/A	14.48	14.48
RYTM Rhythm Pharmaceuticals	N/A	2.79	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
AXSM Axsome Therapeutics	81.49%
NUVL Nuvalent	97.26%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
AXSM Axsome Therapeutics	22.40%
NUVL Nuvalent	10.20%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.72 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
RYTM Rhythm Pharmaceuticals	140	66.42 million	62.37 million	Optionable

AUPH, RYTM, NUVL, and AXSM Headlines

Recent News About These Companies

HC Wainwright Brokers Increase Earnings Estimates for RYTM

23 minutes ago | marketbeat.com

Leerink Partnrs Has Positive Outlook of RYTM Q3 Earnings

August 10 at 2:31 AM | americanbankingnews.com

Leerink Partners Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

August 9 at 10:57 PM | theglobeandmail.com

Leerink Partnrs Issues Positive Outlook for RYTM Earnings

August 9 at 8:08 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

August 8 at 8:25 AM | marketbeat.com

Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term

August 7, 2025 | finance.yahoo.com

Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

August 7, 2025 | marketbeat.com

JMP Securities Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

August 7, 2025 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Misses Estimates By $0.09 EPS

August 6, 2025 | marketbeat.com

Primecap Management Co. CA Sells 783,868 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

August 6, 2025 | marketbeat.com

17,100 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Jefferies Financial Group Inc.

August 6, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

August 5, 2025 | zacks.com

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

August 5, 2025 | globenewswire.com

BIT Capital GmbH Takes $319,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

August 4, 2025 | marketbeat.com

Westfield Capital Management Co. LP Takes $71.04 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

August 4, 2025 | marketbeat.com

Bayforest Capital Ltd Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

August 2, 2025 | marketbeat.com

Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)

August 1, 2025 | insidermonkey.com

Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)

August 1, 2025 | msn.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by XTX Topco Ltd

August 1, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Recommendation of "Buy" by Analysts

August 1, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, RYTM, NUVL, and AXSM Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$11.37 -0.06 (-0.52%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$11.32 -0.04 (-0.40%)

As of 08/8/2025 07:57 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Axsome Therapeutics NASDAQ:AXSM

$104.80 +0.48 (+0.46%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$104.42 -0.38 (-0.37%)

As of 08/8/2025 07:57 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Nuvalent NASDAQ:NUVL

$74.11 +1.95 (+2.70%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$74.88 +0.77 (+1.04%)

As of 08/8/2025 04:37 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$91.98 -0.50 (-0.54%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$91.96 -0.03 (-0.03%)

As of 08/8/2025 06:23 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time